VGLL4

Across TCGA pan-cancer cohorts, VGLL4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VGLL4 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher VGLL4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated VGLL4 expression acts as an unfavorable survival marker, although some lineages such as OV and LUAD show a favorable association.

PDAC, HNSC, and OV are the cancer types where VGLL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.162	0.548	.002	22	view →
HNSC	OS	Tertile	All	0.555	0.821	.003	19	view →
OV	DFS	Tertile	All	1.000	0.571	.045	4	view →
LUAD	OS	Median	All	0.981	0.941	.019	3	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.746	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

VGLL4–PDAC (DFS)

Open the PDAC breakdown →